Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic accuracy of flat panel computed tomography for acute stroke: a systematic review and meta-analysis of diagnostic test accuracy studies.

Clinical radiology·2026
Same author

[Reduction in hospital stay after the implementation of a clinical pathway for patients with pacemaker implantation].

Journal of healthcare quality research·2026
Same author

Quality of life in patients with spontaneous intracranial hypotension: A systematic review and meta-analysis.

Revue neurologique·2025
Same author

Consensus on improving the comprehensive care of patients with acute heart failure.

Revista clinica espanola·2023
Same author

Medical Imaging Compatibility of Magnesium- and Iron-Based Bioresorbable Flow Diverters.

AJNR. American journal of neuroradiology·2023
Same author

Fluoroscopy- and CT-Guided Gold Fiducial Marker Placement for Intraoperative Localization during Spinal Surgery: Review of 179 Cases at a Single Institution-Technique and Safety Profile.

AJNR. American journal of neuroradiology·2023
Same journal

CT Evaluation of Osseous Trauma at the Craniocervical Junction: A Pattern-Based Overview.

AJNR. American journal of neuroradiology·2026
Same journal

Comprehensive Structural MRI Phenotyping in <i>Oligophrenin 1-</i>Related Disorder Reveals Characteristic Brain Malformations.

AJNR. American journal of neuroradiology·2026
Same journal

ASNR-ESNR White Paper on Sustainability in Neuroradiology.

AJNR. American journal of neuroradiology·2026
Same journal

Intracranial Atherosclerotic Disease Distribution Across Circle of Willis Segments: Insights from CREST-H.

AJNR. American journal of neuroradiology·2026
Same journal

Regional Cerebral Blood Flow Patterns on ASL in Subacute Sclerosing Panencephalitis: Quantitative Analysis and Clinical Correlation.

AJNR. American journal of neuroradiology·2026
Same journal

Improved Diagnostic Certainty of Photon-Counting CT Myelography Compared with Energy-Integrating CT for CSF-Venous Fistulas in Spontaneous Intracranial Hypotension.

AJNR. American journal of neuroradiology·2026
See all related articles

Related Experiment Video

Updated: May 24, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Dabigatran (Pradaxa).

J Comin1, D F Kallmes

  • 1St Vincent's Hospital, Melbourne, Australia. julescomin@gmail.com

AJNR. American Journal of Neuroradiology
|February 21, 2012
PubMed
Summary
This summary is machine-generated.

Dabigatran (Pradaxa), a direct thrombin inhibitor, offers a predictable and potent anticoagulant effect. It may replace warfarin due to fewer side effects, interactions, and reduced monitoring needs.

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Related Experiment Videos

Last Updated: May 24, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Dabigatran is a novel oral anticoagulant.
  • It belongs to the direct thrombin inhibitors (DTIs) class.
  • Warfarin is the current standard anticoagulant.

Purpose of the Study:

  • To compare dabigatran with warfarin.
  • To evaluate dabigatran's efficacy and safety profile.

Main Methods:

  • Clinical trials comparing dabigatran and warfarin.
  • Assessment of anticoagulant effect, side effects, and monitoring requirements.

Main Results:

  • Dabigatran demonstrates a more predictable and potent anticoagulant effect.
  • Fewer significant side effects and drug interactions observed with dabigatran.
  • Reduced need for routine monitoring compared to warfarin.

Conclusions:

  • Dabigatran presents a promising alternative to warfarin.
  • Its favorable profile suggests potential for widespread clinical adoption.
  • Direct thrombin inhibitors offer advantages in antithrombotic therapy.